A phase 2 multicenter randomized double-blind placebo-controlled study to assess the efficacy safety and tolerability of AVP-786 (deudextromethorphan hydrobromide [D6-DM]/ quinidine sulfate [Q]) for the treatment of neurobehavioral disinhibition including aggression agitation and irritability in patients with traumatic brain injury (TBI).

Traumatic brain injury (TBI) is a common medical condition with serious and long term sequelae that impact patients ability to function. The neurological insult may induce marked behavioral changes, such as aggression, agitation, and irritability. This behavior is severely destructive to patients and their caregivers. This study is assessing the efficacy of AVP-786 as a serotonin reuptake inhibitor. It is hypothesized that this drug may contribute to treating neurobehavioral disinhibition after TBI.

You may be eligible for this study if you meet the following criteria:

• Conditions: TBD, tbd, tbd
• Age: 99 years or below
• Gender: All